Group 1 - The core viewpoint of the news is the introduction of a comprehensive package of measures to optimize refinancing in the capital market, aimed at supporting high-quality listed companies and enhancing the adaptability for technology innovation enterprises [1][2] - The measures focus on increasing support for high-quality listed companies by optimizing refinancing reviews and improving efficiency, while maintaining a selective approach to ensure quality [2][3] - The new policies allow high-quality companies to direct raised funds towards new industries, new business formats, and new technologies that align with their main business, promoting a second growth curve [2][3] Group 2 - The introduction of a "light asset, high R&D investment" recognition standard for main board listed companies is part of the measures to better meet the refinancing needs of technology innovation enterprises [4][5] - The "light asset, high R&D investment" standard has already proven effective in the Sci-Tech Innovation Board, with 14 companies raising a total of 35.12 billion yuan, indicating its importance in supporting technology enterprises [4][5] - The expansion of this standard to the main board is seen as a key move to enhance refinancing flexibility and support companies with low fixed asset ratios and high intangible asset ratios [5] Group 3 - The refinancing interval for unprofitable companies has been clarified to six months, allowing technology innovation companies to better manage their financing schedules and support their R&D and business development [6][7] - The measures also include stricter regulations on refinancing related to changes in control, requiring companies to publicly commit to completing issuances within the validity period of approvals [8] - Enhanced supervision throughout the refinancing process aims to address issues such as financial fraud and misuse of raised funds, ensuring compliance and accountability [9]

● 本报记者 黄灵灵 黄一灵 为提高对科技创新企业的包容性、适应性，沪深交易所在总结前期科创板、创业板"轻资产、高研发投 入"认定标准试点的基础上，研究推出主板上市公司"轻资产、高研发投入"认定标准。 近年来，主板公司主动跟进前沿科技研发，产业不断转型升级。从目前主板上市公司行业分布来看，部 分上市公司亦涉及新一代信息技术、高端装备制造、生物医药、新材料等战略性新兴产业领域，已集聚 一批具有核心技术能力的上市公司。此类公司具有固定资产占比较低，无形资产比重较高，研发费用持 续增加且占营业收入比例显著高于行业平均水平等特征，经营发展、转型升级与技术迭代、产品创新密 切相关，需要长期、大量、稳定资金支持。 在主板研究推出"轻资产、高研发投入"认定标准，有助于提升募集资金使用的针对性和实效性，更好服 务主板科技型企业，推动传统产业转型升级与新质生产力培育协同发展。 具体来看，主板上市公司"轻资产"认定标准为实物资产占总资产比重不高于20%；"高研发投入"认定标 准为最近三年平均研发投入占营业收入比例不低于15%，或者最近三年累计研发投入不低于3亿元且最 近三年平均研发投入占营业收入比例不低于5%。 有助于上市公司合 ...

Core Viewpoint - United Biomedical, Inc. (UBI) has completed its share reduction plan, decreasing its stake in Shenglian Biomedical (Shanghai) Co., Ltd. from 10.52% to 7.52% through the sale of 12,319,240 shares, which constitutes 3.00% of the company's total share capital [1][2][3]. Shareholder Holding Situation - Before the reduction plan, UBI held 43,199,898 shares, representing 10.52% of the total share capital of Shenglian Biomedical [1]. - The shares were acquired prior to the company's initial public offering and have been tradable since October 28, 2020 [1]. Implementation Results of the Reduction Plan - UBI's reduction plan was disclosed on October 23, 2025, with a maximum intended reduction of 12,319,320 shares [2]. - As of February 9, 2026, UBI successfully reduced its holdings by 12,319,240 shares, achieving the planned reduction [2]. Changes in Equity - Following the reduction, UBI's total shareholding decreased from 33,960,458 shares to 30,880,658 shares, with the ownership percentage dropping from 8.27% to 7.52% [3][4]. - This change in equity does not trigger a mandatory tender offer and will not affect the company's controlling shareholder or actual controller [3][4]. Other Notes - The reduction was executed in compliance with previously disclosed plans and does not involve any changes to the company's governance structure or ongoing operations [4][5]. - UBI has no concerted actions with other parties regarding this shareholding change [3].

Core Viewpoint - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced a change in its continuous supervision sponsor representative due to the work transition of one of the original representatives, ensuring ongoing compliance and oversight of its fundraising activities [1][2]. Group 1 - The company’s initial public offering and listing project on the Sci-Tech Innovation Board has a statutory continuous supervision period from June 19, 2020, to December 31, 2023 [1]. - The original sponsor representatives were Zheng Qianguo and Chen Hengrui, with Zheng Qianguo stepping down due to work changes [2]. - Li Qinhang has been appointed as the new sponsor representative to replace Zheng Qianguo, ensuring the continuity of supervision duties [2]. Group 2 - The company expresses gratitude to Zheng Qianguo for his contributions during the IPO and continuous supervision period [2]. - Li Qinhang holds a bachelor's degree from Nankai University and a master's degree in finance from The Chinese University of Hong Kong, having been involved in investment banking since 2021 [3]. - Li Qinhang has participated in various IPO projects and has a good compliance record in the sponsorship business [3].

Group 1 - The core viewpoint of the news is that Shenzhen aims to significantly increase its GDP from 2.83 trillion yuan in 2020 to 3.87 trillion yuan by 2025, with an average annual growth rate of 5.5%, leading among first-tier cities [1] - Shenzhen's economic and social development goals for 2026 include a GDP growth target of 5% and a stabilization of fixed asset investment, aiming for a growth of 5% [1] - The long-term goal for the "15th Five-Year Plan" period is for Shenzhen's GDP to exceed 5 trillion yuan [1] Group 2 - Shenzhen plans to enhance its manufacturing sector, targeting a growth of over 6% in industrial added value for enterprises above designated size [2] - The city will implement a "20+8" industrial policy system 3.0 to boost the development of key industries such as new-generation electronic information, new energy vehicles, and semiconductor integrated circuits [2] - Shenzhen aims to establish itself as a global leader in artificial intelligence, with a target of over 10% growth in the added value of the AI industry cluster [2] Group 3 - The hosting of the APEC 2026 meeting in Shenzhen is seen as an opportunity to enhance the city's international service level [3] - Shenzhen will focus on optimizing its global trade service system and innovating in service trade, digital trade, and green trade [3] - The city aims to promote a vibrant market that facilitates cross-border trade and strengthens modern supply chain, port logistics, and foreign trade service enterprises [3]

Group 1 - The company, Shanghai Aopumai Biotechnology Co., Ltd., has participated in the establishment of an industrial fund named Shanghai Aochuang Xian Dao Venture Capital Partnership (Limited Partnership), with a total fundraising target of RMB 1 billion [2] - The company and/or its wholly-owned subsidiary, Aopumai Biological Engineering Co., Ltd., plan to contribute no more than 30% of the total fund size, which amounts to a maximum of RMB 300 million [2] - The fund will focus on early to mid-stage projects and mergers and acquisitions in the fields of biomanufacturing, pharmaceutical equipment and consumables, and biomedicine within China [2] Group 2 - The company has signed a partnership agreement with several entities, with an initial investment scale of RMB 500 million [2] - The fund management has completed the private investment fund registration procedures with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [4] - The company acknowledges potential risks in the fundraising process, including the possibility of not reaching the fundraising target due to partners not fulfilling their capital contributions [4]

Core Insights - Shanghai's newly released three-year action plan aims to reshape the city's industrial landscape and extend its reach into near-Earth orbit, targeting an industrial output value exceeding 4 trillion yuan by 2025 and setting ambitious goals for 2028 [1] Group 1: Strong Investment Momentum - Industrial investment in Shanghai is projected to grow by 20.0% year-on-year in 2025, with manufacturing investment showing a remarkable increase of 22.8%, providing a solid foundation for the action plan's three-year goals [2] Group 2: Multi-Path Industrial Structure Optimization - The action plan outlines a comprehensive approach with four major actions and 17 measures, focusing on differentiated strategies for various industry levels, emphasizing optimization for traditional industries and strategic guidance for leading sectors like integrated circuits, biomedicine, and artificial intelligence [3] Group 3: Deep Integration of "AI + Manufacturing" - The action plan highlights the importance of smart and digital transformation, aiming for full coverage of smart factories in large enterprises by 2028, increasing robot density to 600 units per 10,000 people, and achieving over 70% digitalization in smart manufacturing equipment [4] Group 4: Targeting New Trillion-Yuan Markets - In addition to consolidating existing advantages, Shanghai aims to guide investments into emerging fields such as low-altitude economy, commercial aerospace, embodied intelligence, biomanufacturing, and smart terminals [5] Group 5: Financial Incentives for R&D Innovation - The action plan includes attractive financial incentives for R&D, offering tiered subsidies based on research investment levels, with significant support for companies investing over 100 million yuan annually [6] Group 6: Comprehensive Resource Support - To ensure the achievement of goals, the action plan proposes extensive support measures, including financial products with lower interest rates and longer terms, as well as addressing industrial land renewal and talent cultivation [7] Group 7: Transition from "Cost Lowland" to "Ecological High Ground" - Shanghai has been optimizing its business environment, with core cost factors for industrial enterprises decreasing annually, leading to a profit margin of 6.3%, which is 1 percentage point higher than the national average [8][9] Group 8: Modern Industrial System Visualization - Shanghai is set to anchor its new industrialization efforts by high-quality mapping of a "2+3+6+6" modern industrial system by 2026 [10]

Core Viewpoint - Yongtai Bio-B (06978) has announced a conditional agreement to issue new convertible bonds worth RMB 270 million and notes worth RMB 30 million, aimed at repaying existing convertible bonds due on February 20, 2026 [1] Group 1: Convertible Bonds and Notes - The new convertible bonds will have an initial conversion price of HKD 2.92 per share, equivalent to RMB 2.62 [1] - Upon full exercise of the conversion rights attached to the new convertible bonds, a maximum of 103 million shares will be issued, representing approximately 16.66% of the existing issued shares and about 14.28% of the enlarged issued shares after the conversion [1] Group 2: Use of Proceeds - The proceeds from the subscription will be exclusively used for the full and final repayment of the outstanding principal amount of the 2023 convertible bonds [1] Group 3: Conditions and Guarantees - The new convertible bonds and notes will be secured by collateral as outlined in the relevant documentation [1] - Upon receipt of the new convertible bonds and notes, and after the company has paid the accrued unpaid interest on the 2023 convertible bonds, the investors will sign a repayment deed confirming the full and final repayment of the 2023 convertible bonds [1]

Core Insights - The price of experimental monkeys in the market is on the rise, indicating a growing demand and potential supply constraints for this specific type of laboratory animal [2] Company Actions - The company is actively taking measures to ensure a stable supply of experimental monkeys by diversifying procurement channels and deepening cooperation with laboratory animal suppliers [2]

Core Viewpoint - Jiuyuan Gene has submitted an IND application for its innovative drug JY54 injection, aimed at weight management for obese or overweight individuals, marking a significant advancement in the metabolic treatment field [2] Group 1: Product Development - JY54 injection is a long-acting insulin analog designed to manage weight, showcasing Jiuyuan Gene's commitment to innovation in metabolic diseases [2] - The product is a dual receptor agonist (DACRAs) that mimics natural insulin mechanisms, offering multiple actions such as inhibiting glucagon secretion, delaying gastric emptying, and reducing appetite [3] - Clinical pre-research indicates that JY54 injection has demonstrated excellent efficacy and safety, with significant potential for weight loss and metabolic improvement [6] Group 2: Market Positioning - The global obesity and metabolic disease prevalence is rising, making weight management therapies a highly active area for pharmaceutical innovation [3] - JY54 injection's mechanism is believed to have advantages over current GLP-1 drugs, potentially leading to better fat reduction while preserving muscle mass [3] - The product's unique molecular structure supports long-acting administration, enhancing patient compliance and laying the groundwork for future combination therapies with GLP-1 [5] Group 3: Strategic Direction - Jiuyuan Gene's pipeline includes both mature products and innovative therapies, creating a clear gradient layout that addresses current market needs while exploring future treatment advancements [6] - The combination of mature products and innovative pipelines is expected to build a resilient long-term development structure in the metabolic disease sector [6] - The acceptance of the IND application reflects Jiuyuan Gene's ongoing investment in innovative drug development and its ambition to enhance its global influence in the metabolic drug innovation field [6]